Type 2 Diabetes

New England CEPAC
October 29, 2014 10:00AM-4:00PM

Brown University, Providence, RI

The New England CEPAC, a core program of the Institute for Clinical and Economic Review (ICER), convened at a public meeting in October 2014 to discuss management options for patients with type 2 diabetes. ICER's report reviewd the comparative clinical effectiveness and value of multiple pharmacological options for second- and third-line treatment in patients with inadequate glycemic control on metformin monotherapy or a combination of metformin and a sulfonylurea, the most widely accepted initial medication choices for type 2 diabetes. The drug classes assessed in the review include: sulfonylureas, insulin, and two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The New England CEPAC also reviewed the evidence on multiple forms of insulin and methods for insulin delivery, as well as the potential benefits of continuous blood glucose monitoring in this population.

Key Dates

Associated Materials

09/25/2014

09/25/2014

10/29/2014

10/29/2014

10/29/2014

11/06/2014

Public comments received on the Draft Evidence Report.


12/22/2014

12/22/2014
Action Guide For Patients

12/22/2014
Action Guide For Clinicians

12/22/2014
Action Guide For Payers